Description: Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Home Page: www.mymetics.com
BiopOle Center
Epalinges,
1066
Switzerland
Phone:
41 21 653 4535
Officers
| Name | Title |
|---|---|
| Mr. Ronald Kempers | CEO, COO, Pres & CFO |
| Dr. Sylvain Fleury | Chief Scientific Officer |
| Dr. Antonius Johanne Stegmann | Head of R&D and Chief Scientific Officer of Mymetics BV |
| Mr. Mario Amacker Ph.D. | Head of Quality & Manufacturing |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 12.1723 |
| IPO Date: | 1995-03-30 |
| Fiscal Year End: | December |
| Full Time Employees: | 9 |